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ABSTRACT: Background. Although typically associated with a favorable
prognosis, a minority of human papillomavirus (HPV)-related (1) oropha-
ryngeal cancers recur after chemoradiation. We postulated that a minor
HPV-negative tumor subfraction may be responsible for recurrences of
HPV1 oropharyngeal cancer.
Methods. Paired untreated primary and recurrent tumor specimens were
identified for 37 patients with oropharyngeal cancer who received defini-
tive chemoradiotherapy at our institution. Concordance in HPV/p16
expression between primary and recurrent tumors was assessed.
Results. Among 31 patients with HPV1/p161 primary tumors, 30
(97%) retained evidence of both HPV and p16 expression at recurrence
(27 HPV1/p161; 3 HPV1/p16-partial). One (3%) initially HPV1/p161
patient developed an HPV-negative/p16-negative lung squamous cell
carcinoma (SCC), representing either a discordant oropharyngeal cancer
metastasis or second primary tumor.
Conclusion. HPV-related oropharyngeal cancers retain HPV1/p161
expression at recurrence. Our results fail to provide evidence that a
minor HPV-negative tumor subfraction is responsible for biologically
aggressive behavior of HPV1 oropharyngeal cancer that recurs after
chemoradiation. VC 2014 Wiley Periodicals, Inc. Head Neck 37: 8–11,
2015
KEY WORDS: human papillomavirus, p16, oropharyngeal cancer,
expression profiling, chemoradiation
INTRODUCTION
Human papillomavirus (HPV) is the primary causative
factor in the majority of oropharyngeal cancers in
developed countries and is present in over 70% of newly
diagnosed oropharyngeal cancer.1 HPV-associated oropha-
ryngeal cancer represents a distinct disease entity from
non-HPV-associated oropharyngeal cancer, more com-
monly affecting younger patients and former or non-
smokers who often present with smaller primary tumors
and cystic-appearing nodal metastases.2–4 Although HPV-
related oropharyngeal cancer is associated with a more
favorable prognosis than its HPV-negative counterpart,
those patients with a history of heavy tobacco use, matted
lymph nodes, and more advanced tumor (T4) and nodal
(N3) stages remain at significant risk for both locore-
gional and distant failure.2,5–7 The molecular basis of the
uncharacteristically aggressive tumor behavior in these
poorer prognosis HPV1 oropharyngeal cancer subgroups
has yet to be determined.
Overexpression of p16 is a surrogate marker for HPV
infection that can be readily determined by immunohisto-
chemistry (IHC) and is frequently used to determine
HPV-positivity in oropharyngeal cancer.8,9 Although IHC
for p16 is typically unequivocally positive or negative,
partial or even absent p16 immunostaining may occasion-
ally be encountered in HPV1 oropharyngeal cancer.10,11
Similarly, heterogeneous HPV-expression within tumors
has been described.12,13 Such reports have stimulated
speculation that heterogeneous or discordant HPV and
p16 expression may identify tumors in which HPV is
present merely as a “bystander,” which may be associated
with a worse prognosis than “HPV-driven” oropharyngeal
cancer that diffusely expresses both HPV and p16.12 It
may further be hypothesized that the minority of HPV1
oropharyngeal cancers, which demonstrate biologically
aggressive behavior, may be driven by a minor HPV-
negative subpopulation of tumor cells within an otherwise
HPV1 tumor, and would therefore manifest an HPV-neg-
ative/p16-negative phenotype at the time of recurrence.
The poorer prognosis of patients with HPV1 oropharyn-
geal cancer who have a history of heavy smoking
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supports this hypothesis, given the established causal rela-
tionship between smoking and HPV-negative head and
neck squamous cell carcinoma (SCC).2,5,6,14,15 Data to
assess this possibility, however, remain lacking. We
therefore analyzed HPV and p16 expression in recurrent
oropharyngeal cancer to determine whether HPV-
associated oropharyngeal cancer expresses HPV and p16
at the time of recurrence.
MATERIALS AND METHODS
Patients
This study was approved by the University of Michigan
Institutional Review Board. The records of 231 consecu-
tive patients with histologically confirmed, previously
untreated American Joint Committee on Cancer stage III
or IV oropharyngeal SCC who received definitive radio-
therapy and concomitant cytotoxic chemotherapy at the
University of Michigan between May 2003 and October
2010 were retrospectively reviewed. Thirty-eight patients
who experienced biopsy-proven locoregional or distant
recurrence were identified. After excluding 1 patient with-
out available tissue from the time of recurrence, 37
patients with paired tumor tissue from both the time of
primary diagnosis and recurrence were included in the
present study.
Treatment
After routine staging, consisting of clinical examina-
tion, direct laryngoscopy, contrast-enhanced CT, or
fluorodeoxyglucose-positron emission tomography-CT,
and chest imaging, all patients underwent CT simulation
in a 5-point thermoplastic mask for immobilization. All
patients received intensity-modulated radiotherapy
(IMRT) with concurrent cytotoxic chemotherapy, consist-
ing of either weekly carboplatin and paclitaxel (n5 36)
or daily cisplatin and 5-fluorouracil during weeks 1 and 5
(n5 1), with hydration and antiemetics administered per
standard of care. IMRT in all patients consisted of a sin-
gle differentially dosed plan with 70 Gy prescribed to the
gross tumor volume and 56 to 64 Gy prescribed to
clinical target volumes at risk for subclinical disease.
Planning target volumes were created by a 3- to 5-mm
uniform expansion of the gross tumor volumes and clini-
cal target volumes. IMRT was delivered in either 2 Gy
daily fractions (n5 35) or 1.25 Gy twice-daily fractions
(n5 2). All patients were routinely seen in follow-up in
the University of Michigan Departments of Radiation
Oncology, Otolaryngology – Head and Neck Surgery, and
Hematology/Oncology, with clinical examination per-
formed every 6 to 12 weeks and head and neck imaging
(either contrast-enhanced CT or positron emission tomog-
raphy/CT) obtained at 3 months after completion of
chemoradiation and every 3 to 6 months thereafter.
Human papillomavirus and p16 testing
HPV and p16 testing was prospectively performed on
untreated primary tumor tissue either as part of either an
institutional review board-approved tissue microarray
study (n5 35) or as part of routine clinical practice
(n5 2). For specimens collected in the tissue microarray,
HPV expression was determined by an ultrasensitive
method using HPV-MultiPlex Polymerase Chain
Reaction-MassArray (PCR-MA) real time competitive
polymerase chain reaction (PCR) after isolation of DNA
from cored tissue samples using the QIAamp DNA
Formalin-Fixed Paraffin-Embedded Tissue kit (Qiagen,
Valencia, CA), with DNA concentration and purity con-
firmed via NanoDrop spectrophotometer (Thermo Scien-
tific, Waltham, MA). PCR amplification of the E6 region
of 15 discrete high-risk HPV types and matrix-assisted
laser desorption/ionization-time of flight mass spectros-
copy with separation of products on a matrix-loaded sili-
con chip array were performed as previously described.16
For clinically determined cases, HPV expression tested by
in situ hybridization (ISH) on 4-mm sections from
paraffin-embedded tissue blocks containing a representa-
tive sample of primary tumor using the INFORM HPV
ISH assay (Ventana Medical Systems, Tucson, AZ) by a
cocktail directed against a subset of high-risk HPV geno-
types (HPV-16, 18, 33, 35, 39, 45, 51, 52, 56, and 66),
with positive reactions detected using the ISH I View
Blue Plus Detection Kit (Ventana Medical Systems) in
accordance with the manufacturer’s instructions. For all
cases, IHC for p16 was performed per protocol supplied
by the kit (CINtec p16INK4a Histology Kit; mtm Laborato-
ries, Westborough MA). p16 expression was classified
based upon percentage of tumor staining in both the
nucleus and cytoplasm, with >75% staining classified as
positive, 20% to 75% scored as partial, and <20% scored
as negative.
For recurrent tumors, HPV and p16 status was retro-
spectively determined using the HPV ISH and p16 IHC
procedures described above. Concordance between the
molecular characteristics of the primary and recurrent
tumor was determined by the expression of HPV and p16
in each specimen. For cases with discordance between
HPV PCR-MA in the untreated primary tumor and HPV
ISH in the recurrence, confirmatory testing for HPV was
performed on both the primary and recurrent tumor using
ISH for primary tumors initially tested by PCR-MA and
PCR-MA for recurrent tumors initially tested by ISH.
RESULTS
Characteristics for the 37 patient cohort are displayed
in Table 1. The initial primary tumor was HPV1 in 32
patients and HPV-negative in 5 patients. Concordance
between HPV and p16 expression in the untreated pri-
mary tumor was 97% (36 of 37 cases); the only discord-
ant case was in an HPV1/p16-negative T4 N2c tonsillar
SCC in a former 25 pack-year smoker.
Recurrent tumor tissue was obtained from locoregional
recurrence in 16 patients (43%) and distant metastasis in
21 patients (57%), including lung metastases in 9 patients,
mediastinal or hilar lymph nodes in 7 patients, bony
metastases in 4 patients, and a paravertebral soft tissue
metastasis in 1 patient.
Expression of both HPV and p16 in the recurrent tumor
identically matched that of the initial primary tumor in 32
of 37 patients (86%). Among initially HPV1/p161 pri-
mary tumors the rate was 87% (27 of 31). Three of the 5
cases without complete concordance in HPV and p16
expression between the initial and recurrent tumors retained
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concordant HPV expression but demonstrated only partially
positive (20% to 75%) staining for p16, compared with the
diffusely positive staining (>75%) pattern observed in the
initial untreated primary tumor. In 1 of these initially
HPV1/p161 cases, ISH for HPV on the recurrent tumor
was negative, although subsequent PCR on the recurrent
tumor revealed the presence of HPV-16 DNA. Therefore,
30 of 31 cases (97%) of initially HPV1/p161 oropharyn-
geal cancer retained evidence of HPV and p16 expression
at the time of recurrence.
Among the 2 remaining cases with potential discord-
ance between the untreated primary and recurrent tumor,
1 demonstrated discordance in both HPV and p16 expres-
sion, whereas the second demonstrated discordance in
only HPV expression. The first case was a 67-year-old
male 80 pack-year former smoker with a poorly differen-
tiated T4N2cM0 SCC of the base of the tongue, who
experienced a suspected local recurrence within the base
of the tongue immediately adjacent to his original pri-
mary tumor 5 years after completion of chemoradiation.
The original poorly differentiated primary tumor demon-
strated the presence of HPV DNA by both ISH and PCR
and diffuse positive immunostaining for p16, whereas the
moderately differentiated tumor that developed 5 years
later was negative for HPV by both ISH and PCR and
negative for p16 expression by IHC. The second case was
a 51-year-old male 25 pack-year former smoker with a
T4N2c tonsillar SCC, who developed an isolated pulmo-
nary metastasis 3.6 years after completing chemoradia-
tion. The original primary tumor was a poorly
differentiated SCC that contained HPV by PCR, although
ISH for HPV was negative and p16 testing was also nega-
tive. The pulmonary lesion that subsequently developed
was also a poorly differentiated SCC, which tested nega-
tive for HPV by both PCR and ISH and negative for p16
by IHC. If this second case is reclassified as a second pri-
mary lung cancer rather than an oropharyngeal cancer
recurrence, the resulting rate of identical HPV and p16
expression between primary and recurrent tumors is 90%
(27 of 30) for those patients with initially HPV1/p161
primary tumors, with HPV and at least partial expression
of p16 detected in 100% of recurrences. In patients with
initially HPV1/p161 primary tumors (n5 31), a history
of moderate or heavy smoking (ie, >10 pack-years) was
not predictive of discordant HPV or p16 expression in the
recurrent tumor (Fisher’s exact test, p5 .63).
DISCUSSION
In our study comparing concordance of HPV and p16
expression in primary and recurrent oropharyngeal cancer,
97% of recurrences from initially HPV1/p161 oropharyn-
geal cancer demonstrated evidence of HPV and p16 impres-
sion, including 87% with identical HPV and p16 expression
profiles. If the lone patient with discordant HPV-negative/
p16-negative SCC at recurrence is reclassified as a second
primary lung cancer, the rate of concordance of HPV and
p16 expression increases to 100%. Our results, therefore,
do not support the hypothesis that recurrent or metastatic
HPV1 oropharyngeal cancers are driven by an HPV-
negative tumor subfraction. This is true even among those
HPV1 patients with a history of moderate or heavy smok-
ing, whose oropharyngeal tumors may be postulated to be
most likely to harbor an HPV-negative subpopulation, given
the dual relationships between smoking and the develop-
ment of HPV-negative oropharyngeal cancer, as well as
smoking and risk of tumor progression and death in HPV1
oropharyngeal cancer.2,5,6 Nonetheless, even rare instances
of discordance in HPV/p16 expression at recurrence among
initially HPV1/p161 patients warrant further discussion.
In this cohort, only 1 case of initially HPV1/p161 oro-
pharyngeal cancer recurred with an HPV-negative/p16-neg-
ative expression profile. The recurrent tumor in this case
demonstrated a moderate degree of histological differentia-
tion, as compared to poor differentiation in the initial pri-
mary, suggesting the possibility that this recurrent tumor
may, in fact, be a second primary tumor rather than a
recurrence of the original oropharyngeal cancer. This cir-
cumstance is further supported by the clinical picture in
which the second tumor arose after a 5-year disease-free
interval in a former heavy smoker. A similar explanation
TABLE 1. Baseline characteristics.
Characteristic
No. of patients
(%)
Sex
Male 35 (95)
Female 2 (5)
Tumor site
Base of tongue 17 (46)
Tonsil 20 (54)
T classification
1 3 (8)
2 8 (22)
3 6 (16)
4 20 (54)
N classification
0 2 (5)
1 1 (3)
2a 1 (3)
2b 14 (38)
2c 12 (32)
3 7 (19)
AJCC stage
III 1 (3)
IV 36 (97)
Smoking status
Never 11 (30)
Former 11 (30)
Current 15 (40)
Smoking pack-years
<10 15 (41)
>10 22 (49)
HPV and p16 status at diagnosis
HPV1/p161 31 (84)
HPV-negative/p16-negative 5 (13)
HPV1/p16-negative 1 (3)
HPV-negative/p161 0 (0)
HPV genotype among HPV1
patients, n5 32
HPV-16 26 (81.2)
HPV-18 2 (6.2)
HPV-33 2 (6.2)
N/A 2 (6.2)
Abbreviations: AJCC, American Joint Committee on Cancer; HPV, human papillomavirus; N/A,
not available.
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also seems likely in the second instance of discordant HPV
expression at recurrence, which occurred in the patient
with p16- primary tonsillar SCC that was HPV1 by PCR,
but HPV-negative by ISH. The absence of both HPV
expression (by either PCR or ISH testing) and p16 staining
in a suspected solitary lung metastasis 3.6 years after com-
pletion of chemoradiation suggests the possibility of sec-
ond primary lung tumor, rather than a distant metastasis, in
this former heavy smoker. The alternative hypothesis,
namely that the initial positive PCR for HPV represents a
false-positive and that this patient was rather HPV-
negative at presentation and developed a solitary distant
metastasis with matching HPV-negative characteristics,
remains equally plausible.
The 3 cases of initially HPV1/p161 oropharyngeal
cancer that demonstrated a partial p16 expression pattern
at recurrence are additionally noteworthy. In all of these
recurrences, partial p16 expression below the current
standard 75% threshold for p16-positivity was observed,
which stands in contrast to the diffusely positive p16
expression pattern observed in the initial primary tumor.
Such heterogeneous expression of p16 has been previ-
ously described in HPV1 primary tumors at the time of
diagnosis, although not at the time of recurrence, to the
best of our knowledge.10 In contrast to these previous
reports, we did not observe any cases of partial or hetero-
geneous p16 expression at initial presentation in HPV1
tumors in this cohort.
Our study has several strengths, most notably that it is
the first published report to compare HPV and p16
expression profiles between primary and recurrent oropha-
ryngeal cancer. Additionally, HPV and p16 expression
was prospectively ascertained in all untreated primary
tumors using largely uniform methodology, with the
exception of 2 cases for which ISH rather than PCR was
used. Our study also has several potential limitations,
including its retrospective nature, relatively small size,
and the use of different methods used to determine HPV
status in recurrent tumors (ISH) than was used for the
majority of the initially untreated primary tumors (PCR).
We have recently performed an analysis of nearly 300
head and neck cancer cases evaluated by PCR-MA and
ISH for HPV expression, in which discordant cases were
resolved by a second viral L1 consensus PCR followed
by Sanger sequencing of the PCR product to identify the
HPV type. In that study, we show that ISH is less sensi-
tive than PCR-MA and L1 consensus PCR, which is
largely because of the low viral copy number in such
tumors and occasional examples of HPV types not repre-
sented in the assay (unpublished data).
In summary, our study demonstrates a high rate of con-
cordant HPV and p16 expression between recurrent oro-
pharyngeal cancer and the initial primary tumor. These
findings fail to support the hypothesis that chemoradiore-
sistance in HPV-related oropharyngeal cancer is driven by
an HPV-negative tumor subfraction.
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